Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka
Published by Arron Aatkar, PhD

Cantargia has announced that its CAN10 IL1RAP immunology programme has been acquired by Otsuka Pharmaceutical. Deal terms include an upfront payment of US$33m, plus up to US$580m in development, regulatory and commercial milestone payments. The company is also eligible for up to double digits tiered earn-out payments from global product sales. The deal is expected to close within Q325, after which, Otsuka will become responsible for the development and commercialisation of CAN10.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.